Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and JAK-Inhibitor as Bridge to Transplant in MPN
NCT04282187Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Mar 2020
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in Myeloproliferative Neoplasm (MPN), sponsored by University of Washington. Started Mar 2020; status: recruiting.
02
Drugs
decitabine
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04282187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282187.